Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 1, 2008
Genomics!!! I told you so......
Analysis of: New Study Ties Genes To Leukemia Treatment | online.wsj.com
Author: GLG Expert Contributor
Gene mutation analysis can help refine therapy in acute leukemia and impact on results!!
April 30, 2008
Rituxan ( Vitamin R ): Let's not panic!!
Analysis of: Wider Aim for Rituxan Fails | online.wsj.com
Author: GLG Expert Contributor
Rituxan failed to improve various parameters and targets in a rather comprehensive study of patients with Lupus.
April 30, 2008
Phase II Data are Intriguing for Boehringer Ingelheim's BIBF 1120 Pill in Pts with Advanced Lung Cancer
Analysis of: Data suggests promising overall survival and progression-free survival with Vargatef(TM) (BIBF 1120) | www.pipelinereview.com
Author: GLG Expert Contributor
This study is notable for several reasons: (1) it looked at 2 dose of BIBF 1120 and found essentially no difference in tumor control between the higher and lower dose regimens; (2) it included only patients who had previously received chemotherapy, and therefore, by definition, were less likely to have...
April 28, 2008
More potential developments in chronic lymphatic leukemia (CLL) therapy!
Analysis of: IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro | bloodjournal.hematologylibrary.org
Author: GLG Expert Contributor
ZymoGenetic appears to have a biologic that will expedite lymphocytes apoptosis (destruction) when combined with Fludara and Rituxan- 2 standard agents in this rather common & occasional refractory condition.
April 28, 2008
A Non Epo Product for Anemia of Chemotherapy? Will this dog hunt?
Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
Author: GLG Expert Contributor
This non erythropoietin (Epo) product will raise hemoglobin levels and decrease the need for transfusions.
April 25, 2008
Oral PBI-1402 from ProMetic Life Sciences Inc. Might Have the Potential to Fill the Void Left by the EPO Stimulating Agents
Analysis of: Oral PBI-1402 Demonstrates Significant Activity in Chemeotherapy-Induced Anemia Phase II Clinical Trial | www.pipelinereview.com
Author: GLG Expert Contributor
While only a Phase II study, it suggest that Oral PBI-14 may be of significant help to cancer patients who suffer from anemia caused by their chemotherapy. http://www.pipelinereview.com/content/view/19152/109/ This is especially notable given the recent saftey concerns about and decline in use...
April 24, 2008
Advance in Small Cell Lung Cancer (SCLC)?
Analysis of: Poniard reports positive results for lung cancer drug | www.cnbc.com
Author: GLG Expert Contributor
Doubles survival BUT "comparator" arm is best supportive care. See http://investor.poniard.com/ReleaseDetail.cfm?ReleaseID=306218
April 22, 2008
Thalidomide (Celgene) use to be liberalized in Europe
Analysis of: Thalidomide Gets Boost in Europe | online.wsj.com
Author: GLG Expert Contributor
Thalidomide literally started the improved outlook in MM along with, and followed by Velcade, Revlimid and Stem Cell transplants. To now have increased access in Europe should open up that market eventhough the other agents are in widespread use (I think)
April 22, 2008
Wellpoint restricting epo products. Am I surprised?? No!!
Analysis of: WellPoint likely to follow FDA on anemia drugs | www.reuters.com
Author: GLG Expert Contributor
A major insurer (Wellpoint) is using the guidelines of the FDA to restrict erythropoietin (Epo) use.
April 18, 2008
XELOX=FOLFOX! Score one for Roche!
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In MCRC FOLFOX which involves infusional 5FU has been the cornerstone of therapy. This study shows that an oral 5FU substitute, Xeloda, can replace the IV 5FU and expedide care and avoid cumbersome infusions.

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 Next101 to 110 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T01:45:17.000